CHUNDRA BROOKS: Open Payments
NPI 1699116624 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,815 in 69 payments from 16 companies in 2025. Trend: 2023 $1,641 · 2024 $2,905 · 2025 $1,815
Food & beverage: $1,799Education: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $337 |
| Madrigal Pharmaceuticals | 7 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $203 |
| Ardelyx, Inc. | 2 | $145 |
| Regeneron Healthcare Solutions, Inc. | 6 | $140 |
| Gilead Sciences, Inc. | 1 | $128 |
| GENZYME CORPORATION | 5 | $124 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $117 |
| Phathom Pharmaceuticals, Inc. | 3 | $81 |
| PFIZER INC. | 4 | $77 |
Products named: DUPIXENT, REZDIFFRA, IBSRELA, ENTYVIO, Livdelzi, XIFAXAN, SKYRIZI, CREON.
Industry payments across GA — which companies pay providers there.
